

Review Form 1.6

Journal Name:	Journal of Pharmaceutical Research International
Manuscript Number:	Ms_JPRI_82215
Title of the Manuscript:	Epidemiology, Evaluation and Management of Anti-phospholipid Syndrome
Type of the Article	

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<https://www.journalipri.com/index.php/JPRI/editorial-policy>)

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments	<p>aPL profile and thrombotic risk: Anticardiolipin antibodies are a better predictor of arterial and venous thrombosis than LA positive.</p> <p>I recommend and substantiate why anticardiolipin explanations explain a better predictor of thrombotic complications than LA, when the higher thrombotic risk of LA antibodies is generally known.</p> <p>Antibodies to cardiolipin and 2GPI are identified using standardised enzyme-linked immunosorbent assay techniques.</p> <p>The claim that cardiolipin antibodies are identified by standardized ELISA methodologies is not true. ELISA methodologies are not standardized, on the contrary, CLIA methodologies that are standardized have been used recently.</p> <p>There are multiple trials for new type medications are being researched and hopefully can lead to improvement in the management protocols for the syndrome.</p> <p>The claim that there are studies with new drugs should be supplemented by literature. Just as it would be appropriate to conclude by mentioning the new AQPS macros that are being discussed (beta2GPI structure, phosphatidyl serine, annexin)</p>	
Minor REVISION comments		
Optional/General comments		

Comment [PB1]: Jednou je tam LA, pak zase LAC. Rozepsat

Comment [SLdMP2]: nové markery a nové léky

[Review Form 1.6](#)

PART 2:

	Reviewer's comment	Author's comment <i>(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i>
Are there ethical issues in this manuscript?	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	

Reviewer Details:

Name:	Ludek SLavik
Department, University & Country	University Hospital Olomouc, Czechia